Tag: VKTX

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viking Therapeutics (VKTX – Research Report), Ansell (ANSLF – Research Report) and Corbus Pharmaceuticals (CRBP – Research Report) with bullish sentiments.

Viking Therapeutics (VKTX)

Oppenheimer analyst Jay Olson maintained a Buy rating on Viking Therapeutics today and set a price target of $138.00. The company’s shares closed last Friday at $76.45.

According to TipRanks.com, Olson is a 5-star analyst with an average return of 18.4% and a 43.7% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Crispr Therapeutics AG, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viking Therapeutics with a $113.50 average price target, implying a 54.0% upside from current levels. In a report issued on March 27, Stifel Nicolaus also maintained a Buy rating on the stock with a $95.00 price target.

See the top stocks recommended by analysts >>

Ansell (ANSLF)

Jefferies analyst Vanessa Thomson upgraded Ansell to Buy today and set a price target of A$30.85. The company’s shares closed last Thursday at $15.05.

Thomson has an average return of 90.1% when recommending Ansell.

According to TipRanks.com, Thomson is ranked #2050 out of 8789 analysts.

Currently, the analyst consensus on Ansell is a Hold with an average price target of $18.08.

Corbus Pharmaceuticals (CRBP)

Oppenheimer analyst Jeff Jones maintained a Buy rating on Corbus Pharmaceuticals today and set a price target of $58.00. The company’s shares closed last Friday at $39.97.

According to TipRanks.com, Jones is a 5-star analyst with an average return of 24.5% and a 38.3% success rate. Jones covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Fusion Pharmaceuticals, and AN2 Therapeutics, Inc.

Currently, the analyst consensus on Corbus Pharmaceuticals is a Moderate Buy with an average price target of $55.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VKTX:

• Viking Therapeutics Stock (NASDAQ:VKTX): Analysts Stay Bullish on 2024’s Top Mid-Cap
• 3 Best Stocks to Buy Now, 3/28/2024, According to Top Analysts 
• Viking Therapeutics price target raised to $138 from $116 at Oppenheimer
• Viking (NASDAQ:VKTX): Positive Trial Data Boosts Stock
• Viking Therapeutics price target raised to $125 from $100 at BTIG